GlassScriptPhysician profile
Chris J Radpour
NPI 1174599401
$1,778.31
in general payments reported to CMS, 2019-2025
25 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $27.96 · 2021: $136 · 2022: $278 · 2023: $441 · 2024: $447 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $308.51 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $243.94 | 2019-2023 | |
| Aspira Women'S Health INC | $125.00 | 2021-2023 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $110.75 | 2022-2025 | |
| Myovant Sciences INC. | $102.91 | 2022 | |
| Axonics, INC. | $99.49 | 2024 | Axonics, Bulkamid |
| Channel Medsystems, INC. | $82.82 | 2023 | |
| Sumitomo Pharma America, INC. | $79.14 | 2024 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $71.38 | 2022-2024 | Slynd |
| Daiichi Sankyo INC. | $58.48 | 2019-2023 | Injectafer |
| Sage Therapeutics, LLC | $57.83 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $53.03 | 2019-2023 | Gardasil 9 |
| Therapeuticsmd, INC. | $52.13 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $49.69 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $47.32 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $42.76 | 2024-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Allergan, INC. | $41.21 | 2019 | |
| Pfizer INC. | $39.39 | 2023-2024 | |
| Lupin INC. | $20.86 | 2019 | |
| Organon LLC | $19.55 | 2024 | |
| Intuitive Surgical, INC. | $19.03 | 2019 | |
| Becton, Dickinson and Company | $16.14 | 2019 | |
| Avion Pharmaceuticals | $13.52 | 2021 | |
| Amgen INC. | $12.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Radpour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.